STOK logo

STOK
Stoke Therapeutics Inc

1,008
Mkt Cap
$2.11B
Volume
449,012.00
52W High
$40.22
52W Low
$8.30
PE Ratio
-241.75
STOK Fundamentals
Price
$35.90
Prev Close
$35.61
Open
$36.14
50D MA
$34.30
Beta
1.29
Avg. Volume
986,806.54
EPS (Annual)
-$0.1163
P/B
6.00
Rev/Employee
$1.08M
$1,598.60
Loading...
Loading...
News
all
press releases
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational...
Business Wire·6d ago
News Placeholder
More News
News Placeholder
Baillie Gifford & Co. Purchases New Position in Stoke Therapeutics, Inc. $STOK
Baillie Gifford & Co. purchased a new stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities...
MarketBeat·9d ago
News Placeholder
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational...
Business Wire·14d ago
News Placeholder
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational...
Business Wire·15d ago
News Placeholder
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Analysts
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the twelve ratings firms that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation, nine have...
MarketBeat·22d ago
News Placeholder
Stoke Therapeutics Stock Up 340% as Chair Sells $174K in Shares
Key PointsThe chair of Stoke Therapeutics disclosed selling 4,355 shares for roughly $174,000 at around $40.00 per share on March 10, 2026...
Nasdaq News: Markets·26d ago
News Placeholder
Stoke Therapeutics (NASDAQ:STOK) Sees Unusually-High Trading Volume - Still a Buy?
Stoke Therapeutics (NASDAQ:STOK) Sees Strong Trading Volume - Here's What Happened...
MarketBeat·27d ago
News Placeholder
Assenagon Asset Management S.A. Boosts Position in Stoke Therapeutics, Inc. $STOK
Assenagon Asset Management S.A. boosted its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 36.4% in the fourth quarter, according to its most recent disclosure with the...
MarketBeat·28d ago
News Placeholder
Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally
Key PointsThe chief medical officer of Stoke Therapeutics disposed of 14,311 Common Stock shares for a transaction value of $457,000 across three days ending March 19, 2026...
Nasdaq News: Markets·30d ago
News Placeholder
FY2030 Earnings Estimate for STOK Issued By HC Wainwright
Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Equities researchers at HC Wainwright issued their FY2030 EPS estimates for Stoke Therapeutics in a research note issued on Friday, March 20th. HC Wainwright analyst A. Ghosh anticipates that the company will earn $4.03 per share for the year. H...
MarketBeat·1mo ago
<
1
2
...
>

Latest STOK News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.